Type 2 diabetes
Conditions
Interventions
Administration of Canagliflozin 100 mg once a day post breakfast.
Sponsors
Medical Center for Translational and Clinical Research, Hiroshima University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetes 2. >=20 of age at the time of informed consent acquisition 3. Type 2 diabetes with HbA1c (NGSP) >=6.0% and <10.0% 4.The patient provided written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: 1. Has history of hypersensitivity to Canagliflozin 2. Has history of administration of SGLT2 inhibitor within 4 weeks before initiation of the study 3.patient with insulin dependent diabetes mellitus 4. Has history of myocardial infarction, angina, cerebral infarction, intracranial hemorrhage, subarachnoid hemorrhage, transient ischemic attacks within 3 months before initiation of the study 5. patient with ASO 6. With severe renal dysfunction (eGRF <45 mL/min or patient undergoing artificial dialysis) 7. Has history of severe ketosis, diabetic coma, or precoma within 6 months 8. Has history of cancer, severe infection 9. Pregnant, possibly pregnant, planned to become pregnant or nursing women 10. Are considered not eligible for the study by the attending doctor due to other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in FMD from baseline to 2 hours and 12 weeks | — |
Countries
Japan
Contacts
Public ContactYukihito Higashi
Hiroshima University Hospital Medical Center for Translational and Clinical Research
Outcome results
None listed